Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-09-08
2010-06-29
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S196110, C424S227100, C530S328000, C530S300000
Reexamination Certificate
active
07744898
ABSTRACT:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
REFERENCES:
patent: 3645852 (1972-02-01), Axen et al.
patent: 4235877 (1980-11-01), Fullerton
patent: 4428941 (1984-01-01), Galibert et al.
patent: 4487715 (1984-12-01), Nitecki et al.
patent: 4559230 (1985-12-01), David et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4659569 (1987-04-01), Mitsuhashi et al.
patent: 4818527 (1989-04-01), Thornton et al.
patent: 4882145 (1989-11-01), Thornton et al.
patent: 4935235 (1990-06-01), Rutter et al.
patent: 5017558 (1991-05-01), Vyas
patent: 5019386 (1991-05-01), Machida et al.
patent: 5039522 (1991-08-01), Neurath
patent: 5100662 (1992-03-01), Bolcsak et al.
patent: 5133961 (1992-07-01), Ellis et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5158769 (1992-10-01), Neurath et al.
patent: 5780036 (1998-07-01), Chisari
patent: 5788969 (1998-08-01), Chisari
patent: 5840303 (1998-11-01), Chisari
patent: 5932224 (1999-08-01), Chisari
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6235288 (2001-05-01), Chisari
patent: 6322789 (2001-11-01), Vitiello et al.
patent: 6419931 (2002-07-01), Vitiello et al.
patent: 6607727 (2003-08-01), Chisari et al.
patent: 2003/0021809 (2003-01-01), Chisari
patent: 2003/0171538 (2003-09-01), Chisari
patent: 105 481 (1984-04-01), None
patent: 013 828 (1987-03-01), None
patent: 271 302 (1987-12-01), None
patent: 293 201 (1988-11-01), None
patent: 326 111 (1989-01-01), None
patent: 327 369 (1989-08-01), None
patent: 469 281 (1993-06-01), None
patent: 431 327 (1996-04-01), None
patent: 534 615 (2001-01-01), None
patent: 2 034 323 (1980-06-01), None
patent: 60-161999 (1985-08-01), None
patent: 64-025800 (1989-01-01), None
patent: WO 93/03753 (1993-03-01), None
patent: WO 94/19011 (1993-03-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 94/25060 (1994-11-01), None
patent: WO 95/03777 (1995-02-01), None
patent: WO 95/04817 (1995-02-01), None
Moriarty et al (Science 227:429-433, 1984).
Heathcote et al (Hepatology 30:531-536, 1999).
DiBrino et al (Journal of Immunology 151 (11): 5930-5935, 1993).
Depla et al (Journal of Virology 82:435-450, 2008).
Aggarwal et al. “Oral salmonella: Malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells”J. Exp. Med,1990, 172:1083-1090.
Aichele et al “Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide”J. Exp. Med,1990, 171:1815-1820.
Bertoletti, A. et al. “Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells”Nature,Jun. 2, 1994, 369:407-410.
Bertoletti “HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B nucleocapsid antigen”Proc. Natl. Acad. Sci.USA, 1991, 88:10445-10449.
Bessler, W.G. et al. “The synthetic analog of bacterial lipoprotein are potent immunoadjuvants in combination with or covalently linked to antigen”Prog. Leukocyte Biol.,1986, 5:337-344.
Bevan “Stimulating killer cells”Nature,1989, 342:478-479.
Bhatnagar et al. “Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the determinant”Proc. Natl. Acad. Sci.USA, 1982, 79:4400-4404.
Bichko, V. et al. “Subtype ayw variant of hepatitis B virus”FEBS Letters,Jun. 1985, 185(1):208-212.
Bowie, J.U. et al. “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”Science,Mar. 1990, 247:1306-1310.
Braciale et al. “Class I major histocompatibility complex-restricted cytolytic T lymphocytes recognize a limited number of sites on the influenza hemagglutinin”Proc. Natl. Acad. Sci.USA, 1989, 86:277-281.
Buller et al. “Induction of cytotoxic T-cell responses in vivo in absence of CD4 helper cells”Nature,1987, 328:76-79.
Carbone et al. “Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides”J. Exp. Med,1988, 167:1767-1779.
Carbone, F.R. and Bevan, M.J. “Induction of Ovalbumin-Specific Cytotoxic T Cells by in Vivo Peptide Immunization”J. Exp. Med.,Mar. 1989, 169:603-612.
Cassell et al. “Linked recognition of helper and cytotoxic antigenic determinants for the generation of cytotoxic T lymphocytes”Ann. N.Y. Acad. Sci,1991, pp. 51-60.
Celis et al. “Recognition of hepatitis B surface antigen by human T lymphocytes”J. Immunol,1988, 140:1808-1815.
Chisari et al. “Hepatitis B virus structure and biology”Microbial Pathogenesis,1989, 6:311-325.
Collins, D.S. et al. “Processing of Exogenous Liposome-Encapsulated Antigens In Vivo Generates Class I MHC-Restricted T Cell Responses”J. Immunology,1992, 148:3336-3341.
De Magistris, M.T. et al. “Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor”Cell,Feb. 21, 1992, 68(4):625-634.
Deres et al. “In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine”Nature,1989, 342:561-564.
Falk et al. “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules”Nature,1991, 351:290-296.
Ferrari et al. “Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen”J. Clin. Invest,1991, 88:214-222.
Fujii et al. “Peptide chemistry 1983” published 1984 by Protein Research Foundation (OSAKA), pp. 215-220.
Galibert et al. “Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned inE. Coli” Nature,1979, 281:646-650.
Golvano et al. “Polarity of immunogens: Implications for vaccine design”Eur. J. Immunol,1990, 20:2363-2366.
Gotch et al. “Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes”J. Exp. Med,1988, 163:2045-2057.
Gotch et al. “Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in associate with HLA-A2”Nature,1987, 326:881-882.
Greenstein, J.L. et al. “A Universal T Cell Epitope-Containing Peptide From Hepatitis B Surface Antigen can Enhance Antibody Specific for HIV gp120”J. Immunology,1992, 148:3970-3977.
Guilhot et al. “Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: Production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines”J. Virol,1992, 66:2670-2678.
Hayashi et al. “Studies on peptides CLXVI. Solid-phase synthesis and immunological properties of fragment peptides related to human hepatitis B virus surface antigen (HBsAg) and its pres-S2 gene”Chem. Pharm. Bull.,1988, 32:4993-4994.
Hilleman, M.R. “Comparative Biology and Pathogenesis of AIDS and Hepatitis B Viruses: Related but Different”AIDS Res. and Human Retroviruses,1994, 10(11):1409-1419.
Hopp, T.P. “Immunogenicity of a synthetic HBsAg peptide: enhancement by conjugate to a fatty acid carrier”Mol. Immunol.,1984, 21:13-16.
Ishioka et al. “Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo”J. Immunol,1989, 143:1094-1100.
Ishioka et al. “Class I MHC-restricted, peptide-specific cytotoxic T lymphocytes generated by peptide priming in vivo”Vaccines90, Cold Spring Harbor Press pp. 7-11, 1990.
Jameson, S.C. et al. “Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells”J. Exp. Med.,Jun. 1, 1993, 177(6):1541-1550.
Kast et al. “Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytot
Mosher Mary E
Saliwanchik Lloyd & Saliwanchik
The Scripps Research Institute
LandOfFree
Peptides for inducing cytotoxic T lymphocyte responses to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides for inducing cytotoxic T lymphocyte responses to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for inducing cytotoxic T lymphocyte responses to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4205641